Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Action to Be Taken against Novartis “Not Yet Decided”: Health Minister
February 4, 2015
- MHLW Calls for Suspension of Manufacturing, Import of Products Using Bovine-Derived Ingredients Originating in Norway
February 4, 2015
- Dr Fukui of St. Luke’s Tapped as Health Sciences Council Chair
February 3, 2015
- MHLW Compiles Requirements for Legally Recognized Clinical Research Core Hospitals
February 3, 2015
- Review Time Targets for New Drugs Revised: PFSB
February 3, 2015
- NIID to Evaluate Prototype Strains for Cell Culture-Based Influenza Vaccines
February 3, 2015
- MHLW Orders Package Insert Revision for Zytiga to Include Hypokalemia as Significant Adverse Reaction
February 3, 2015
- Wholesalers Settled FY2014 Drug Prices with 70% of Customers at December-End: Official
February 2, 2015
- PAFSC First Committee Backs Approval of Takeda’s Once-Weekly DPP-4 Inhibitor
February 2, 2015
- PM Abe Promises to Introduce Patient-Initiated Mixed-Care System while Maintaining Universal Healthcare
January 30, 2015
- Drug Wholesalers Should Stress Annual Price Cuts “Infeasible”: Ex-Minister
January 30, 2015
- MHLW Warns of Severe Febrile Neutropenia for Cabazitaxel
January 30, 2015
- Drug Discovery Support Project for Academia to Receive 3-Fold Budget Increase in FY2015
January 30, 2015
- Chuikyo’s HTA Panel Holds First Closed-Door Meeting
January 29, 2015
- Expenditure for Senshin-Iryo Services Totaled 17.4 Billion Yen: MHLW
January 29, 2015
- Chuikyo Approves Insurance Reimbursement for Companion Diagnostic for Zelboraf
January 29, 2015
- Government Releases Strategy for Dementia
January 28, 2015
- Prof. Hashida of Kyoto University Elected as PAFSC Chairman
January 28, 2015
- Panel OKs Requirements to Give Legal Status to Clinical Research Core Hospitals
January 27, 2015
- Panel on Unapproved Drugs Weighs Revamp upon Rollout of New Development Request Scheme
January 27, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…